NCT06228053View on ClinicalTrials.gov

Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

SX-682

Specified dose twice daily

DRUG

Enzalutamide

Specified dose once daily

Trial Locations (6)

27710

RECRUITING

Duke University, Durham

48109

RECRUITING

University of Michigan, Ann Arbor

53792

RECRUITING

University of Wisconsin, Madison

55455

NOT_YET_RECRUITING

University of Minnesota, Minneapolis

90095

RECRUITING

University of California, Los Angeles, Los Angeles

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Syntrix Biosystems, Inc.

INDUSTRY